EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Triggering global regulatory submissions this year for the treatment of obesity
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
cSCC is one of the most common cancers in the U.S. and globally
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Subscribe To Our Newsletter & Stay Updated
